1 week Ago By ABMN Staff
Pictet Asset Management Holding SA increased its holdings in shares of Organon & Co. ( NYSE:OGN – Free Report ) by 5.8% during the fourth quarter, Holdings Channel reports.
The fund owned 52,348 shares of the company’s stock after purchasing an additional 2,861 shares during the period. Pictet Asset Management Holding SA’s holdings in Organon & Co. were worth $781,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB raised its stake in shares of Organon & Co. by 32.
4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares during the last quarter. Beam Wealth Advisors Inc.
raised its position in Organon & Co. by 3.9% in the 4th quarter.
Beam Wealth Advisors Inc. now owns 18,888 shares of the company’s stock worth $282,000 after purchasing an additional 717 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Organon & Co.
by 0.5% during the 4th quarter. HighTower Advisors LLC now owns 163,440 shares of the company’s stock worth $2,439,000 after buying an additional 855 shares in the last quarter.
CIBC Asset Management Inc boosted its position in Organon & Co. by 4.9% in the 4th quarter.
CIBC Asset Management Inc now owns 25,523 shares of the company’s stock valued at $381,000 after buying an additional 1,184 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its stake in shares of Organon & Co. by 24.
3% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company’s stock valued at $93,000 after buying an additional 1,222 shares during the period. 77.
43% of the stock is owned by institutional investors and hedge funds. Organon & Co. Price Performance Shares of OGN opened at $12.
54 on Tuesday. The stock has a market cap of $3.23 billion, a P/E ratio of 3.
76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73.
Organon & Co. has a 1 year low of $12.15 and a 1 year high of $23.
10. The stock’s 50-day moving average price is $15.08 and its two-hundred day moving average price is $15.
94. The company has a current ratio of 1.70, a quick ratio of 1.
21 and a debt-to-equity ratio of 17.73. Organon & Co.
Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend.
This represents a $1.12 dividend on an annualized basis and a dividend yield of 8.93%.
The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.
63%. Analysts Set New Price Targets Several equities analysts have recently issued reports on OGN shares. Barclays cut their price target on Organon & Co.
from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th.
TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley dropped their price target on shares of Organon & Co.
from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th.
One analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Organon & Co.
presently has an average rating of “Hold” and an average price target of $20.80. Check Out Our Latest Research Report on Organon & Co.
About Organon & Co. ( Free Report ) Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Read More Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. ( NYSE:OGN – Free Report ).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.
com's FREE daily email newsletter ..
